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The full-length pro-survival protein Mcl-1 predominantly resides on the outer membrane of mito-
chondria. Here, we identiﬁed a mitochondrial matrix-localized isoform of Mcl-1 that lacks 33 amino
acid residues at the N-terminus which serve both as a mitochondrial targeting and processing
signal. Ectopically-expressed Mcl-1 without the N-terminal 33 residues failed to enter the mitochon-
drial matrix but retained wt-like activities both for interaction with BH3-only proteins and anti-
apoptosis. In contrast, the mitochondrial matrix-localized isoform failed to interact with BH3-only
proteins and manifested an attenuated anti-apoptotic activity. This study reveals that import of
Mcl-1 into the mitochondrial matrix results in the attenuation of Mcl-1’s anti-apoptotic function.
Structured summary:
MINT-7965637: NOXA (uniprotkb:Q9JM54) physically interacts (MI:0915) with Mcl-1 (uniprotkb:P97287)
by anti tag coimmunoprecipitation (MI:0007)
MINT-7965699: Mcl-1 (uniprotkb:P97287) physically interacts (MI:0915) with Bim (uniprotkb:O43521)
by anti bait coimmunoprecipitation (MI:0006)
MINT-7965655: Mcl-1 (uniprotkb:P97287) physically interacts (MI:0915) with NOXA (uniprotkb:Q9JM54)
by anti bait coimmunoprecipitation (MI:0006)
MINT-7965711: Bim (uniprotkb:O43521) physically interacts (MI:0915) with Mcl-1 (uniprotkb:P97287)
by anti tag coimmunoprecipitation (MI:0007)
MINT-7965673: PUMA (uniprotkb:Q9BXH1) physically interacts (MI:0915) withMcl-1 (uniprotkb:P97287)
by anti tag coimmunoprecipitation (MI:0007)
MINT-7965685:Mcl-1 (uniprotkb:P97287) physically interacts (MI:0915) with PUMA (uniprotkb:Q9BXH1)
by anti bait coimmunoprecipitation (MI:0006)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction various stimuli [5–7]. Germline deletion of the Mcl-1 gene re-The anti-apoptotic Bcl-2 family proteins including Bcl-2, Bcl-xL
and Mcl-1 inhibit the mitochondria-dependent apoptosis path-
way through blocking mitochondrial outer membrane permeabi-
lization triggered by the activation of pro-apoptotic Bcl-2 family
members [1,2]. Like other anti-apoptotic Bcl-2 family members,
Mcl-1 contains four Bcl-2 homology (BH) domains (BH1-4) and
a C-terminal hydrophobic tail. The latter domain was shown to
be essential for its targeting to intracellular membranes [3,4]. En-
forced expression of Mcl-1 delays apoptotic cell death induced bychemical Societies. Published by E
lity; mMcl-1, mouse Mcl-1;
ondrial processing peptidase
iology, Academia Sinica, 128
Fax: +886 2 2782 6085.
ang-Yen).sulted in peri-implantation lethality of mouse embryos [8]. Con-
ditional knockout and promoter knock-in mouse models further
revealed that Mcl-1 is essential for the survival of many cell types
in the organism [9–14].
Mcl-1 expression is regulated both at transcriptional [15–17]
and post-transcriptional levels. The best characterized post-tran-
scriptional modiﬁcation is phosphorylation, which is related to
its protein stability [18,19]. It has long been noticed that Mcl-1
from cells under normal growth conditions exists as two major
bands during immunoblotting analysis [4,20,21]. Interestingly,
the ratio of these two isoforms varies in different tissues [14,20].
One recent study indicated that the fast-mobility (FM) isoform of
human MCL-1 is an N-terminal truncation product [20]. However,
how such isoform is generated and the functional signiﬁcance of
such truncation remains unclear. Here, we provide evidence that
the FM isoform of the mouse Mcl-1 (mMcl-1) doublet is generatedlsevier B.V. All rights reserved.
Fig. 1. The FM isoform of mMcl-1 is an N-terminally truncated product. (A) The SM
isoform is much more labile than the FM isoform. Immunoblot analysis was carried
out for protein lysates from Ba/F3 cells treated with cycloheximide (CHX) (30 lg/
ml) for 0–4 h as indicated. The blot was probed with mMcl-1 or HSP 60 antibodies.
(B) The SM but not the FM isoform could be recognized by the N20 antibody.
Protein lysates from NIH3T3 cells treated with or without CHX for 4 h were
immunoprecipitated with control, N20 or mMcl-1 speciﬁc antibodies. Immune
complexes were subjected to immunoblot analysis using mMcl-1 speciﬁc antibod-
ies. G.S., pre-immune goat serum; R.IgG, control rabbit IgG. (C) The FM isoform co-
migrated with ectopically-expressed DN33. Endogenous (from Ba/F3 cells) or
ectopically-expressed mMcl-1 (wt or DN33 overexpressed in HeLa cells) were
immunoprecipitated with mMcl-1 or N20 antibodies and the immune complexes
along with the input lysates (total [T] or from puriﬁed mitochondria [M]) were
subjected to immunoblot analysis using mMcl-1 speciﬁc antibody.
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of Mcl-1 is attenuated.
2. Materials and methods
2.1. Expression vectors
The expression vectors encoding wt or various mMcl-1 mu-
tants (DN33, 3RG, DC31, DN33-DC31, 3RG-DC31, Su9-DN33)
or the EGFP fusion proteins [N33-EGFP, EGFP-C31, N33-EGFP-
C31, N33(3RG)-EGFP] were all constructed into the pcDNA3 vec-
tor (Invitrogen, Carlsbad, California) by standard PCR-assisted
mutagenesis-coupled cloning methods. pwtMcl-1-IRES-EGFP,
p-DN33-IRES-EGFP and pSu9-DN33-IRES-EGFP are another set
of mammalian expression vectors which can co-express EGFP
along with wt or mutant mMcl-1 as indicated in the construct
names. All constructs involving mutagenesis were conﬁrmed by
sequencing.
Additional materials and methods including cell lines, antibod-
ies, mass spectrometry, sub-mitochondrial localization analysis
and siRNA knockdown are listed in the Supplementary data.
3. Results and discussion
3.1. The FM isoform of the mMcl-1 doublet is an N-terminal truncation
product without the ﬁrst 33 amino acid residues
Endogenous mMcl-1 existed as one major doublet during
immunoblotting analysis (Fig. 1A, lane 1). A very minor band in be-
tween these two major bands could occasionally be observed in a
gel with a longer running time (Fig. 1A). Treatment of Ba/F3 cells
with the protein synthesis inhibitor cycloheximide diminished
the level of the slow-mobility (SM) isoform much faster than that
of the FM isoform (Fig. 1A). On the other hand, an antibody raised
against the N-terminal 20 amino acids of the full-length protein
(N20 antibody) speciﬁcally immunoprecipitated the SM but not
the FM isoform of the mMcl-1 doublet (Fig. 1B). Edman degrada-
tion analysis of the FM isoform immunoprecipitated from protein
lysates prepared from the normal culture of Ba/F3 cells showed
that the sequence of the ﬁrst 7 amino acid residues of this protein
was VAEEAKA (Fig. S1A). Together, these results suggest that the
SM isoform is a labile full-length protein, whereas the FM isoform
is a cleavage product without the N-terminal 33 amino acids that is
much more stable than the SM isoform.3.2. The FM isoform of mMcl-1 is localized to the mitochondrial matrix
Sequence analysis using the MitoProt II program [22] revealed
that the N-terminal region of mMcl-1 contained a candidate
mitochondrial targeting signal (amino acid residues 1–33) and a
cleavage site was predicted to be between amino acid residues
33(L) and 34(V). If this is the case, the FM isoform would then
be generated inside mitochondria after the full-length protein is
imported into this organelle by the putative mitochondrial target-
ing signal. Density-gradient fractionation analysis of Ba/F3 cells
revealed that majority (>90%) of the FM isoforms were indeed
localized to the mitochondria-enriched fractions (fractions 11–
14, Fig. S1B), which manifested a similar electrophoretic mobility
as the recombinant mMcl-1 lacking N-terminal 33 amino acids
(DN33) that was transiently overexpressed in HeLa cells (com-
pare lanes 3 and 5 of Fig. 1C). Moreover, the following two obser-
vations further support the prediction that the FM isoform
localized to mitochondria lacks N-terminal 33 amino acids. First,
the N20 antibody failed to recognize the endogenous FM isoform
detected in the mitochondria-enriched fractions of Ba/F3 cells(compare lanes 3 and 4 of Fig. 1C). Second, LC/MS/MS analysis re-
vealed that a short peptide with the sequence of VAEEAK, indica-
tive of an endogenous cleavage event between Leu-33 and Val-34
of mMcl-1 (Fig. S1A), was identiﬁed in the trypsin-digested FM
isoform puriﬁed from the mitochondria-enriched fractions of Ba/
F3 cells (Fig. S1C).
Next, we examined the sub-mitochondrial compartment where
the FM isoform resided. To address this issue, mitochondria puri-
ﬁed from Ba/F3 cells were subjected to proteinase K treatment.
As shown in Fig. 2A, whereas the SM isoform, like the outer mem-
brane protein Tom70, was degraded following proteinase K diges-
tion, the FM isoform remained to be protected under such
treatment. Upon swelling of mitochondria, the FM isoform still re-
mained protected from proteinase K digestion like the matrix-
localized protein HSP60, whereas the intermembrane space
(IMS)-localized Smac was completely degraded. Similar pattern
of protection was also observed for the FM isoform and HSP60
when isolated mitochondria were solubilized in various concentra-
tions of digitonin (0.01–0.3%, see Supplementary Materials and
methods) during the proteinase K treatment step (Fig. 2B). Next,
to examine whether the FM isoform was associated with mem-
brane, puriﬁedmitochondria were subjected to alkaline treatments
[23,24]. As shown in Fig. 2C, at pH 10.8, the FM isoform was mainly
in the pellet fraction. However, at pH 11.5 nearly all FM isoform
was extracted to the supernatant fraction, a result that was very
similar to the case with the matrix protein HSP60. Taken together,
these results suggest that, unlike the SM isoform that resides on
the outer membrane of mitochondria (MOM), the bulk portion of
the FM isoform is localized to the matrix, although the possibility
Fig. 2. The bulk portion of the FM isoform is localized to the mitochondrial matrix. (A) Puriﬁed mitochondria from Ba/F3 cells were subjected to swelling or pre-treatment
with 1% Triton-X100 (TX100) prior to proteinase K digestion and immunoblotting analysis using antibodies against the indicated proteins. (B) Same as in (A) except that
puriﬁed mitochondria were re-suspended in a buffer containing increasing concentration of digitonin (0.01–0.3%) during the proteinase K digestion step. Both (A) and (B)
were run as two blots, a longer run to resolve Mcl-1 isoforms, and a shorter run to visualize the IMS marker, Smac. (C) Puriﬁed mitochondria were subjected to extraction in
the carbonate buffer (pH 10.8 or 11.5), and the samples separated into the membrane (p) and soluble (s) fractions were analyzed by immunoblotting using antibodies speciﬁc
to the indicated proteins.
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bic tail, is loosely associated with the inner membrane can not be
completely ruled out.
3.3. The N-terminal 33 amino acids of mMcl-1 serve both as a
mitochondrial targeting and processing signal, and the targeting
speciﬁcity of this leader peptide is enhanced by mMcl-1’s C-terminal
hydrophobic tail
We next examined whether ectopically-expressed mMcl-1
without N-terminal 33 amino acid residues (DN33) could be tar-
geted to mitochondria, given that it still retains the C-terminal
hydrophobic tail (Fig. 3A) that can potentially anchor or target to
such organelle. As shown in Fig. 3B, approximately 35% of ectopi-
cally-expressed wt mMcl-1 was targeted to mitochondria and
40% of this mitochondrial fraction was the FM isoform (panel i).
Under the same conditions, less than 5% of ectopically-expressed
DN33 was targeted to mitochondria (panel ii). Of note, unlike the
FM isoform, all mitochondria-targeted, ectopically-expressed
DN33 was eliminated after proteinase K digestion (Fig. 3C, com-
pare lanes 2 and 5 in the upper panel), suggesting that the latter
one was only loosely associated with the cytosolic side of the
MOM. On the other hand, a protein band with a size slightly smal-
ler than that predicted forDC31 (Mcl-1 without C-terminal 31 ami-
no acids) was detected in the mitochondrial fraction of cells
expressing DC31 (Fig. 3B, panel iii, bands in lanes 10–13 marked
by an asterisk; see also Fig. S2A for a shorter exposure for lanes
1–8 and a longer exposure for lanes 9–16). Such band remained in-
tact after proteinase K digestion of isolated mitochondria (Fig. 3C,lower panel, lane 2), suggesting that it was a cleavage product of
DC31 that was generated inside mitochondria. Further analysis re-
vealed that mutation of all three Arg residues to Gly at positions 5,
6 and 32 of the WT (3RG) or the DC31 mutant protein (3RG-DC31)
or deletion of both N-terminal and C-terminal ends of Mcl-1
(DN33-DC31) abolished both mitochondrial targeting as well as
the appearance of their corresponding cleavage products in the
mitochondria-enriched fractions (panels iv–vi). Those very minor
portion of intact 3RG, 3RG-DC31 or DN33-DC31 that did appear
in the mitochondrial fractions (<5%) were still sensitive to protein-
ase K digestion (Fig. 3C, lane 8 of the upper panel and lanes 5 and 8
of the lower panel), suggesting that they were only loosely associ-
ated with the MOM.
Next, we examined whether the N-terminal 33 amino acids
alone of mMcl-1 (hereafter referred to as N33-AAs) were sufﬁcient
to direct a heterologous protein to mitochondria. To address this
issue, HeLa cells transiently expressing EGFP or various EGFP chi-
meras containing mMcl-1 N-terminal 33 and/or C-terminal 31 res-
idues (C31) were analyzed (Fig. 4A). The results (Fig. 4B and C)
showed that EGFP was localized to most sub-cellular compart-
ments except mitochondria. In contrast, a signiﬁcant fraction of
N33-EGFP was targeted to mitochondria, albeit a large part of
which was still targeted to extra-mitochondrial regions. Interest-
ingly, although C31 itself, was insufﬁcient to direct EGFP exclu-
sively to mitochondria (EGFP-C31), fusion of C31 to the C-
terminus of N33-EGFP (N33-EGFP-C31) markedly enhanced such
process. Of note, those N33-EGFP targeted to mitochondria were
not only resistant to proteinase K digestion (Fig. 4D, compare lanes
4 and 5), but also manifested a faster mobility than those localized
Fig. 3. Subcellular localization of wt and various mMcl-1 mutants. (A) Schematic representation of wt and mutant mMcl-1 expressed in the experiments shown in (B) and (C).
(B) The post-nuclear lysates of HeLa cells transiently expressing the indicated proteins were processed over the 2.5–27.5% (wt/vol) linear iodixanol gradient. Fractions from
each gradient were analyzed by immunoblotting with antibody speciﬁc to each protein as indicated. (C) Puriﬁed mitochondria from HeLa cells expressing wt or various
mutants of mMcl-1 were subjected to proteinase K treatment (+PK) in buffers containing or not containing TX100, followed by immunoblotting analysis using antibodies
speciﬁc to the indicated proteins.
Fig. 4. mMcl-1 N-terminal 33 residues can serve as a mitochondria targeting and processing signal. (A) Schematic representation of various EGFP chimeras containing mMcl-
1 N-terminal 33 and/or C-terminal 31 residues. (B) HeLa cells transiently expressing the indicated EGFP chimera were analyzed by confocal ﬂuorescence microscopy. EGFP
(green), Mitotracker (red), DAPI (white). (C) Same as in (B) except that cell lysates from equal cell equivalent of un-fractionated (total), cytosolic or mitochondrial fractions
were subjected to immunoblot analysis using antibodies speciﬁc to the indicated proteins. ‘‘Short” and ‘‘long” denote two different exposures for that blot. (D) Mitochondria
puriﬁed from HeLa cells transiently expressing the indicated EGFP chimera were subjected to PK treatment as that described in the legend to Fig. 3C.
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Fig. 5. The FM isoform is generated in the mitochondria via an MPP-mediated
cleavage reaction. (A) Generation of the FM isoform from wt mMcl-1 or the mature
form from Su9-DN33 was inhibited by valinomycin or PTO. HeLa cells transiently
expressing the indicated protein were treated with valinomycin (1 lM) or PTO
(200 lM) for 18 h before their cell lysates were analyzed by immunoblotting using
mMcl-1 or HSP60-speciﬁc antibody. (B) Knockdown expression of hMPP-bmarkedly
reduced the generation of the FM isoform or the mature form (m) from wt mMcl-1
or the Su9-DN33 mutant, respectively. (Upper panel) Semi-quantitative RT-PCR
analysis of hMPP-b and GapdhmRNA expression in HeLa cells transfected with #9 or
#11 siRNA (see Supplementary Materials and methods) or an irrelevant control
vector (GFP, C). (Lower panel) HeLa cells transfected ﬁrst with #9 or #11 siRNA,
followed by another transfection with expression vectors encoding wt or the Su9-
DN33 mutant of mMcl-1 were analyzed by immunoblotting using antibody speciﬁc
to mouse (m) or human (h) Mcl-1 or HSP60 as indicated. p, i, and m refer to the
precursor, intermediate and mature form of Su9-DN33, respectively. The interme-
diate form generated from wt mouse or human Mcl-1 is marked by asterisks.
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other hand, although a much more complicated band pattern
was observed for N33-EGFP-C31 that was targeted to mitochon-
dria, most of which were resistant to proteinase K digestion
(Fig. 4D, compare lanes 13 and 14, see also Supplementary Discus-
sion). Taken together, these results suggest that N33-AAs can in-
deed serve as a mitochondrial targeting signal with a slightly
loose speciﬁcity, but such speciﬁcity can be markedly increased
by the C-terminal hydrophobic tail of mMcl-1.
3.4. The FM isoform is generated in the matrix via a mitochondrial
processing peptidase (MPP)-mediated cleavage reaction
We next examined what enzymes might be involved in the gen-
eration of the FM isoform inside mitochondria. Treatment of HeLa
cells with valinomycin, which dissipates the mitochondrial mem-
brane potential (DW), blocked the generation of the FM isoform
from ectopically-expressed wt mMcl-1 (Fig. 5A, compare lanes 1
and 4). Moreover, such cleavage event was blocked when transfec-
ted cells were treated with a broad-spectrum metallo-protease
inhibitor, 1,10-phenathroline (PTO) (Fig. 5A, compare lanes 1 and
7). In contrast, the generation of the predicted size of ectopically-
expressed DN33 which did not get imported into or processed in-
side mitochondria (Fig. 3) was not affected by valinomycin or PTO
treatment (Fig. 5A, compare lanes 2, 5 and 8). These results to-
gether with the matrix-localized nature of the FM isoform suggest
that such isoform might be generated in the matrix of mitochon-
dria via a mitochondrial processing peptidase (MPP)-mediated
cleavage reaction. To test this possibility, we ﬁrst generated an
mMcl-1 mutant (Su9-DN33) that could be cleaved by MPP in the
matrix as a positive control for the knockdown experiment to be
described below. Su9-DN33 is an mMcl-1 mutant in which the
N-terminal 33 amino acids of mMcl-1 were replaced with a candi-
date matrix targeting and processing presequence (amino acid res-
idues 1–58) derived from the mouse homolog of the neurospora
ATP synthase subunit 9, which is a known substrate of MPP in
the mitochondrial matrix [25]. As expected, Su9-DN33 was specif-
ically imported into mitochondria (Fig. S4A) and was processed to
become a mature form that manifested a very similar electropho-
retic mobility (Fig. 5A, compare lanes 1 and 3) and sensitivity to
proteinase K/digitonin treatment in isolated mitochondria as the
FM isoform generated from wt mMcl-1 (Fig. S4B). Mass spectrom-
etry analysis further supported that the mature form of Su9-DN33
was equivalent to the FM isoform of endogenous mMcl-1 (data not
shown). Moreover, as predicted, the generation of an FM-like mol-
ecule from Su9-DN33 was markedly impaired in cells treated with
valinomycin or PTO (Fig. 5A, lanes 6 and 9 vs. lane 3).
We next examined whether knockdown of MPP would interfere
with the generation of the matrix form of Mcl-1. As shown in
Fig. 5B, as expected, the generation of the mature form (equivalent
to the FM isoform) from Su9-DN33 was markedly impaired in cells
transfected with #11 siRNA that could efﬁciently knockdown the
expression of the b subunit of human MPP (hMPP-b), but not in
cells transfected with #9 siRNA whose knockdown efﬁciency was
extremely poor. We next examined the processing of endogenous
human(h) MCL-1 as well as ectopically-expressed mMcl-1 in
hMPP-b knockdown cells. In parental HeLa cells or cells transfected
with control siRNA (#9), three prominent isoforms of hMCL-1 were
observed (Figs. S5B and 5B). Like the FM isoform of mMcl-1, the
fastest-migrating form of hMCL-1 (hFM) failed to be detected by
the N20 antibody (Fig. S5A) and was likely generated inside the
matrix because its sensitivity to proteinase K/digitonin treatment
and alkaline extractability in isolated mitochondria were very sim-
ilar to the matrix marker HSP60 (Fig. S5, B and C). Under conditions
when hMPP-b expression was down-regulated (Fig. 5B, #11 but
not #9 siRNA), the generation of the fastest-migrating form ofendogenous MCL-1, i.e., the hFM isoform, was speciﬁcally impaired
(Fig. 5B, lanes 2 and 4 vs. lanes 1 and 3). Similar results were ob-
served with the ectopically-expressed mMcl-1, i.e., the generation
of the FM isoform was markedly reduced in cells transfected with
#11 but not #9 siRNA (Fig. 5B, compare lanes 1 and 2). Taken to-
gether, these results indicate that Mcl-1 is imported into the mito-
chondrial matrix where it is cleaved by MPP to become the FM
isoform. Of note, when the generation of the FM isoformwas inhib-
ited by chemical inhibitors or siRNA speciﬁc to hMPP-b, a marked
accumulation of an intermediate form of ectopically-expressed
(mouse) or endogenous (human) Mcl-1 (bands marked by asterisks
in Fig. 5A and B) was observed. Given the accumulation of the SM
isoform under such treatment conditions was only marginal; these
3328 C.-R. Huang, H.-F. Yang-Yen / FEBS Letters 584 (2010) 3323–3330results suggest that Mcl-1 is processed to become the FM isoform
via at least two steps, only one of which involves MPP.
3.5. The matrix-localized FM isoform fails to interact with Bim, NOXA
or PUMA
We next carried out co-immunoprecipitation (co-IP) experi-
ments to examine whether the FM isoform could still interact
with those BH3-only proteins that were known to interact with
Mcl-1, i.e., Bim, NOXA and PUMA. As shown in Fig. 6A, while the
mMcl-1 antibody could immunoprecipitate both SM and FM iso-
forms and co-immunoprecipitate all three BH3-only proteins
tested (lanes 5, 13 and 23), antibodies recognizing the tagged
BH3-only proteins (HA or FLAG) could co-immunoprecipitate
the SM but not the FM isoform (lanes 7, 15 and 25 vs. input ly-
sates on lanes 1, 3 and 21, respectively). [Note that the blot
shown in Fig. 6 was exposed to an extent that the FM isoform
was only faintly detected so that it would not be masked by
the enriched SM isoform that was caused by co-expression of
BH3-only proteins; see also Supplementary Results andFig. 6. The matrix-localized FM isoform fails to interact with BH3-only proteins. (A and
expressing vectors in combination with constructs expressing various BH3-only protein
antibodies. Immune complexes along with 1/5 input lysates (lanes labeled with no ‘‘–” IP
R.IgG and M.IgG refer to puriﬁed total rabbit and mouse IgG, respectively.Fig. S6.] In contrast, under the same conditions, ectopically-ex-
pressed DN33, which could not enter the matrix, could be co-
immunoprecipitated with all three BH3-only proteins tested
(lanes 11, 19 and 29, Fig. 6A). We next compared the BH3-only
protein-binding activity of the precursor and mature forms (i.e.,
the matrix-localized FM-like isoform) of mMcl-1 generated from
CHOP cells expressing Su9-DN33. As shown in Fig. 6B, unlike the
precursor (p) and intermediate (i) forms, the mature (m) form of
Su9-DN33 failed to be co-immunoprecipitated by antibodies
recognizing the tagged BH3-only proteins (HA or FLAG) (lanes
11, 15 and 19), albeit it was clearly present in the cell lysates
as revealed in the input lysates (lanes 2–4) or immune com-
plexes precipitated by the mMcl-1 antibody (lanes 9, 13 and
17). Together, these results indicate that the FM isoform is dis-
tinct from the SM isoform in terms of its ability to interact with
BH3-only proteins. Of note, the ectopically-produced DN33,
which fails to enter the matrix, behaved differently from the ma-
trix-localized FM isoform in this co-IP experiment, albeit the
amino acid sequence of these two proteins is presumably
identical.B) Cell lysates from CHOP cells transiently transfected with wt or mutant mMcl-1
s as indicated were immunoprecipitated with mMcl-1, HA-tag, FLAG-tag or control
Ab) were analyzed by immunoblotting using mMcl-1 or the indicated tag antibody.
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attenuated
Given that the FM isoform failed to interact with BH3-only pro-
teins, we next examined whether its anti-apoptotic function was
affected. To address this issue, we took advantage of our observa-
tion that the FM isoform of mMcl-1 was always the predominant
form (>90%) found in cells transiently transfected with the
Su9-DN33 expressing vector alone (Figs. 7B and S7A). For this
experiment, Ba/F3 cells were transfected with vectors that could
co-express EGFP along with wt mMcl-1, DN33 or Su9-DN33, and
the transfected cells were subjected to apoptosis treatments (UV
or Etoposide). For unknown reasons under every DNA dose tested,
total steady-state levels of mMcl-1 (counting both precursor and
processed forms and normalized to the level of co-expressed EGFP)
produced from cells transfected with the Su9-DN33 expression
vector (pSu9-DN33-IRES-EGFP) were consistently more (10-fold)
than that from cells transfected with either the wt mMcl-1 or the
DN33 expression vector (Figs. 7B and S7A). Repeated dose–re-
sponse experiments indicated that maximum protection against
UV or Etoposide-induced apoptosis was reached for each construct
when 5–10 lg of DNA was used, albeit higher levels of protein
expression could still be achieved when more DNA (e.g. 15 lg)
was used in our assay system (Fig. S7).We next carried out a de-
tailed analysis to compare the anti-apoptotic activity of Mcl-1 pro-
duced from these three expression vectors at their maximum
effective dose (15 lg). As shown in Fig. 7A, both wt mMcl-1 and
DN33 expressing cells manifested similar protection from either
UV or Etoposide treatment. In contrast, Su9-DN33-expressing cells,
even with a higher steady-state level of mMcl-1 produced, were
consistently slightly less protected (10%) from either apoptosis
treatment compared to wt mMcl-1 or DN33 expressing cells
(Fig. 7A). Notably, the difference in the apoptosis protection effect
was even more prominent when the comparison was made be-
tween constructs that produced similar levels of proteins, e.g.
1 lg of of Su9-DN33 compared to 15 lg of wt or DN33 expression
vectors (Fig. S7). Given that the FM isoform constituted majority of
the steady-state levels of mMcl-1 molecules present in the Su9-
DN33-expressing cells (>90%), this result suggests that the anti-
apoptotic activity of the matrix-localized FM isoform is attenuated
compared to its precursor SM isoform or the DN33 mutant thatFig. 7. The anti-apoptotic activity of the matrix-localized FM isoform is attenuated. (A)
mMcl-1 along with EGFP were subjected to apoptosis treatments (UV or Etoposide ‘‘ETO”
(EGFP+) that underwent apoptosis was analyzed by staining with annexin-V, followed
experiments (the statistical signiﬁcance between the indicated two groups [marked b
immunoblotting analysis of the steady-state levels of mMcl-1 isoforms (from wt or muta
Su9, Su9-DN33.fails to enter the matrix. The extent of attenuation may be under
estimated in this assay, because a minor amount of non- or par-
tially processed forms of Su9-DN33 could still be detected in
Su9-DN33-expressing cells (Fig. S7A), which can bind to BH3-only
proteins (Fig. 6B) and likely still retain some anti-apoptotic
activity.
Taken together, this result suggests that import of mMcl-1 into
the mitochondrial matrix, but not the cleavage of its N-terminal 33
amino acids per se, results in the attenuation of mMcl-1’s anti-
apoptotic function. Mcl-1 was shown to interact with Puma via
its BH1 domain, but not through its N-terminus [26], the results
present in this study further suggest an intriguing possibility that
the matrix-localized FM isoform undergoes a yet-to-be-deter-
mined modiﬁcation, which bars it from interacting with BH3-only
proteins. Below are possible scenarios: (1) loss of interaction may
simply be due to a topological barrier between the matrix-local-
ized, FM isoform and the BH3-only proteins that are localized to
other compartments of mitochondria; (2) the existence of a mito-
chondrial matrix-speciﬁc adaptor protein, which forms a stable
complex with the matrix-localized, FM isoform and masks the
interacting domain of Mcl-1 with BH3-only proteins; (3) The ma-
trix-localized, FM isoform itself undergoes a post-translational
modiﬁcation and/or a conformational change which affects its
interaction with BH3-only proteins. The ‘‘topological barrier” mod-
el is least favored among the three scenarios, because the co-
immunoprecipitation experiment was carried out using total cell
lysates where topological barrier has been eliminated. More exper-
iments will be required to address these possibilities.
We previously reported that hMCL-1 was loosely associated
with the MOM [3]. Due to the poor resolution of the three isoforms
of hMCL-1 in this earlier study, the matrix-localized feature of the
fastest-migrating isoform of hMCL-1 (hFM) was not noticed at that
time. Here, with a much better resolution of the mMcl-1 doublet,
we noticed that some fractions of the SM isoforms were loosely
associated with the MOM, while other fractions seemed to be sta-
bly integrated into this membrane as revealed by the alkaline
treatment experiment. Notably, the ratio of the SM and FM iso-
forms varies in different tissues [14,20]. It would be interesting
to investigate what molecular mechanism may regulate the ratio
of these two isoforms in different cell types and/or under different
physiological conditions.Ba/F3 cells transiently transfected with expressing vectors encoding wt or mutant
). Twenty-four hours after apoptosis treatments, the percentage of transfected cells
by ﬂow cytometric analysis. Data shown are means ± S.E. from three independent
y a bracket] is as follows: *p < 0.05; **p < 0.01; n.s., p > 0.05). Panel B shows the
nt proteins) in the transfected populations (EGFP+) prior to the apoptosis treatment.
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